Soleno Therapeutics SLNO 深 沪
已收盘 05-18 16:00:00 美东时间
53.01
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 53.01
- 总市值 276.29万
- 52周最高 90.3199
- 市盈率 静 135.61
- 换手率 0.00%
- 52周最低 29.43
- 委 比 0.00%
- 总股本 5.21万
- 历史最高 90.3199
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.81
- 每 手 1
- 风险率 9.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Unicycive Therapeutics announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. With over 25 years of global biopharmaceutical experience, Manning brings expertise in commercialization and product launches. She previously led the U.S. launch of VYKAT™ XR at Soleno Therapeutics and contributed to the FDA approval of BESREMi® at PharmaEssentia. Manning will serve on the Audit, Compensation, and Nominating and Corporate Gove...
10-01 11:05
Kura Oncology appoints Jennifer Fulk as CFO
Kura Oncology (KURA) on Tuesday announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. After more than 15 years at Eli Lilly and Company, Fulk served in a...
09-08 19:24
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
Kura Oncology appoints Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. With over 20 years of experience in biopharmaceutical finance, Fulk previously held senior roles at Eli Lilly, Talkspace, and Soleno Therapeutics. Her expertise in commercial operations, R&D portfolio management, and investor relations is expected to support Kura's growth and value creation. Fulk will oversee capital allocation and execution to maximize ...
09-08 11:00
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Rhythm Pharmaceuticals announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer effective August 17, 2026. Dr. Joshi brings over two decades of leadership experience in drug development, regulatory processes, and lifecycle management. His expertise will support Rhythm’s advancements in next-generation MC4R agonists and its leadership in rare neuroendocrine diseases. Previously, Dr. Joshi served as Chief Development Officer a...
08-17 12:00
Neurocrine slips as safety issues linked to Vykat XR resurface
Shares of Neurocrine Biosciences (NBIX) slipped in the premarket on Wednesday after safety concerns linked to Vykat XR, a rare disease therapy the company added with its acquisition of Soleno Therapeu...
08-12 19:29
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Ovid Therapeutics announced several key leadership appointments to strengthen its executive team. Kevin Norrett was appointed Chief Business Officer, Charles Carter promoted to Chief Financial Officer, Eliseo Salinas joined as Executive R&D Advisor, and Victoria Fort became Chief Strategy Officer. These changes aim to support the company's growth and strategic initiatives in developing innovative treatments for brain disorders.
07-08 11:00
Cantor Fitzgerald Suspends Neutral Rating on Soleno Therapeutics
Cantor Fitzgerald suspends Neutral rating on Soleno Therapeutics (NASDAQ:SLNO).
05-19 20:58
Soleno Therapeutics Completes Merger and Delists from Nasdaq
The latest update is out from Soleno Therapeutics ( ($SLNO) ). On May 18, 2026,...
05-18 21:58
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong earl...
05-18 20:46
